250
Participants
Start Date
July 31, 2012
Primary Completion Date
February 28, 2015
Study Completion Date
February 29, 2016
AAV1/SERCA2a (MYDICAR)
Single intracoronary infusion 1 x 10\^13 DNase Resistant Particles (DRP) MYDICAR
Placebo
Single intracoronary infusion
Birmingham
La Jolla
Long Beach
San Diego
Sylmar
Newark
Jacksonville
Miami
Augusta
Iowa City
Alexandria
Boston
Kansas City
St Louis
New York
The Bronx
Winston-Salem
Columbus
Oklahoma City
Philadelphia
Charleston
Rapid City
Germantown
Tullahoma
Houston
San Antonio
Salt Lake City
Tacoma
Waukesha
Aalst
Leuven
Aalborg
Coppenhagen
Hvidovre
Bad Nauheim
Berlin
Cologne
Dresden
München
Budapest
Debrecen
Ashkelon
Holon
Jerusalem
Rehovot
Groningen
Gdansk
Wroclaw
Zabrze
Malmo
Örebrö
Stockholm
Glasgow
London
Lead Sponsor
Celladon Corporation
INDUSTRY